China Vanke (02202) Appoints Xu Enli as New Chairman of the Board

China Vanke Co.,Ltd. (02202) has announced that Mr. Xu Enli has been elected as the Chairman of the 21st Board of Directors, with his term set to last until the expiration of this board's tenure. Concurrently, Mr. Xu Enli has been appointed as the company's legal representative, and the necessary business registration modifications will be processed in accordance with legal procedures.

The company has also formed its Audit Committee, comprising independent non-executive directors Mr. Liao Zibin and Mr. Wang Weiguo, as well as non-executive director Mr. Lei Jiangsong. Mr. Liao Zibin has been elected as the convener of this committee. Meanwhile, the Remuneration and Nomination Committee includes independent non-executive directors Mr. Huang Yaying and Mr. Yang Zhao, alongside employee representative director Ms. Li Na, with Mr. Huang Yaying serving as convener. The Investment and Decision-Making Committee consists of independent non-executive director Mr. Yang Zhao, executive director Mr. Huang Yu, and non-executive director Mr. Zhu Zhiqiang, with Mr. Yang Zhao acting as convener. Additionally, the Independent Director Special Committee for the 21st Board comprises independent non-executive directors Mr. Liao Zibin, Mr. Huang Yaying, Mr. Wang Weiguo, and Mr. Yang Zhao, who elected Mr. Liao Zibin as convener.

Following a nomination by the Chairman and a review by the Remuneration and Nomination Committee, Mr. Huang Yu has been reappointed as the company's President, effective until the end of the 21st Board's term. Similarly, Mr. Tian Jun has been reappointed as the Board Secretary, also lasting until the board's term concludes. Upon the President's nomination and committee review, Mr. Li Feng, Ms. Hua Cui, and Mr. Li Gang have been reappointed as Executive Vice Presidents, while Ms. Han Huihua has been reappointed as Executive Vice President and Chief Financial Officer, all with terms ending at the same time. Finally, Mr. Huang Yu and Mr. Tian Jun have been jointly appointed as the company's authorized representatives under Rule 3.05 of the Listing Rules.